Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Hongkong
  4. Hong Kong Stock Exchange
  5. Shanghai Junshi Biosciences Co., Ltd.
  6. Nieuws
  7. Andere talen
    1877   CNE100003FF7

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

(1877)
  Rapport
Vertraagde tijd Hong Kong Stock Exchange  -  09:08:14 06-02-2023
37.80 HKD   -2.83%
02/02Chinese regelgever aanvaardt Junshi Bio's nieuwe geneesmiddelenaanvraag voor de behandeling van hyperlipidemie
MT
02/02Zhejiang Huahai Pharma gaat API's leveren aan Junshi Biosciences
MT
01/02Shanghai Junshi Biosciences Unit tekent productie- en leveringsovereenkomst voor anti-COVID-19 geneesmiddel
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
02/02Chinese Regulator Accepts Junshi Bio's New Drug Application for Hyperlipidemia Treatmen..
02/02Zhejiang Huahai Pharma to Supply APIs to Junshi Biosciences
01/02Shanghai Junshi Biosciences Unit Signs Manufacturing, Supply Deal for Anti-COVID-19 Dru..
31/01Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance..
31/01Shanghai Junshi Bio to Widen 2022 Loss as R&D Expenses Balloon
30/01Junshi Biosciences Announces Approval for Marketing of VV116 in China
30/01Shanghai Junshi Biosciences Co., Ltd. Announces Approval for Marketing of VV116 in Chin..
30/01Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended Dec..
30/01China Issues Conditional Approval For Two Local COVID-19 Drugs
29/01China approves two domestically developed COVID drugs
18/01Junshi Biosciences Announces Acceptance of NDA for VV116 in China
18/01Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China
18/01Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC ..
18/01Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC ..
18/01Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC ..
18/01China Accepts Junshi Bioscience's New Drug Application for COVID-19 Drug
18/01Shanghai Junshi Biosciences' Phase III Study for Lung Cancer Treatment Meets Primary En..
11/01Shanghai Junshi Biosciences Obtains Regulatory Approval for Adalimumab Supplemental Dru..
03/01Shanghai Junshi Biosciences Completes Phase III Clinical Study for COVID-19 Drug; Share..
02/01Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvi..
02/01Chinese Regulator Accepts Shanghai Junshi Biosciences' New Drug Application for Migrain..
2022Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigationa..
2022Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Vers..
2022Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 S..
2022Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Dr..
2022Shanghai Junshi's License Application for Nasopharyngeal Carcinoma Treatment Still Unde..
2022Coherus BioSciences Shares Slip 9.6% on Lack of FDA Response to Toripalimab Application
2022Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Dr..
2022Shanghai Junshi Biosciences Co., Ltd. and Hikma Pharmaceuticals PLC Sign Exclusive Lice..
2022Junshi Biosciences Forms Licensing Deal With UK Drugmaker Hikma
2022Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License ..
2022Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License ..
2022Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License ..
2022Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA anti..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I stud..
2022Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA anti..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes
2022Shanghai Junshi Raises 3.7 Billion Yuan From Issuance of A Shares
2022European Regulator Accepts Shanghai Junshi's Market Authorization Application for Lung ..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization A..
2022Junshi Biosciences Announces Submission of a Marketing Authorization Application for To..
2022Junshi Biosciences Announces Submission of a Marketing Authorization Application for To..
2022Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for To..
2022Junshi Biosciences Announces Approval of Supplemental Application for Additional Indica..
2022Chinese Regulator Approves Additional Indications for Shanghai Junshi's Adalimumab Inje..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Su..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization..
2022Junshi Biosciences Announces Submission of a Marketing Authorization Application to the..
2022Junshi Biosciences Announces Submission of a Marketing Authorization Application to the..
2022Chinese Regulator Approves Shanghai Junshi Bioscience's A Share Issuance; Shares Climb ..
2022Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Tria..
2022Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ende..
2022Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01,..
2022Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publicatio..
2022Coherus, Junshi Publish Positive Results From Toripalimab Study
2022China Approves Supplemental New Drug Application for Junshi Biosciences' Lung Cancer In..
2022Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with C..
2022Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in ..
2022Shanghai Bourse Deems Junshi Biosciences' A-Share Issuance Compliant with Listing Rules
2022Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Upda..
2022Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended ..
2022Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for J..
2022Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigationa..
2022Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Tria..
2022Chinese Regulator Accepts Shanghai Junshi Biosciences's Drug, Supplemental Applications
2022Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indi..
2022Shanghai Junshi Biosciences Co., Ltd Receives the Acceptance Notice for the Investigati..
2022Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental Appl..
2022China approves Genuine Biotech's HIV drug for COVID patients
2022Shanghai Junshi Gets European Commission Designation for Nasopharyngeal Cancer Treatmen..
2022Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address with Effect from Augu..
2022Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm..
2022Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm..
2022Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation fro..
2022Chinese Regulator OKs Shanghai Junshi's Clinical Trial Application for Cancer Treatment
2022Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Is..
2022Shanghai Junshi's Resubmission of Biologics License Application for Toripalimab Gets US..
2022Coherus BioSciences Says FDA Accepts Resubmission of Biologics License Application for ..
2022Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Torip..
2022Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Torip..
2022Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Accept..
2022Coherus, Junshi: FDA Accepts Resubmission of Toripalimab Application
2022Shanghai Junshi Obtains FDA Investigational Drug Approval for Breast Cancer Treatment; ..
2022Shanghai Junshi Biosciences Co., Ltd. and Risen Pharma Tech Co., Ltd. Announces FDA App..
2022Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director
2022Shanghai Junshi Biosciences Lowers Expected Total Proceeds for Proposed Issuance
2022Shanghai Junshi Biosciences Obtains Approval for Clinical Trial of EGFR Inhibitor Table..
2022Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) ..
2022Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) ..
2022Shanghai Junshi Gets Chinese Regulator's Approval for Clinical Trial of Investigational..
2022Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Da..
2022Junshi Biosciences JV Cleared to Start Clinical Trial in China of Cancer Drug
2022Chinese Shares Rebound; Junshi Jumps 4% in Shanghai as COVID-19 Tablet Finishes Clinica..
2022VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Mod..
2022Shanghai Junshi Biosciences Co., Ltd. Announces PAXLOVID Phase III Registrational Trial..
2022Junshi Completes Clinical Trials For COVID-19 Tablet
2022Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatme..
2022Chinese Shares Rebound; Junshi Jumps 7.7% in Shanghai as COVID-19 Drug Shows Promise
2022Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea..
2022Junshi Bio's Cancer Drug Wins New Indication in China; Shares Slide 7%
Volgende evenement op SHANGHAI JUNSHI BIOSCIENCES CO., LTD.